{{medical}}
{{drugbox
| IUPAC_name = (''RS'')-1-(1-adamantyl)ethanamine
| image = (±)-Rimantadine enantiomers structural formulae.png
| width = 280px
| CAS_number = 13392-28-4
| ATC_prefix = J05
| ATC_suffix = AC02
| PubChem = 5071
| DrugBank = APRD01219
| smiles = CC(N)C12CC3CC(C1)CC(C2)C3
| C = 12 |H = 21 |N = 1
| molecular_weight = 179.302 [[克|g]]/[[摩尔_(单位)|mol]]
| bioavailability = 容易吸收
| protein_bound = 40%
| metabolism = 在[[肝脏|肝脏]]中被[[羟基化|羟基化]]并与[[葡糖醛酸结合|葡糖醛酸结合]]
| elimination_half-life = 25.4 ± 6.3 小時
| excretion = [[肾脏|肾脏]]
| pregnancy_category = C <small>（美國）</small>
| legal_US = Rx-only
| legal_CN = Rx
| routes_of_administration = 口
}}

'''金刚乙胺'''（{{lang|en|Rimantadine}}）是一种[[抗病毒药|抗病毒药]]，属于三环胺类，对[[A型流感病毒|A型流感病毒]]有预防和治疗作用，且作用强于金刚烷胺。金刚乙胺的中枢神经副作小于金刚烷胺。金刚乙胺通过抑制特异蛋白的释放，而干扰病毒脱壳，它能抑制[[逆转录酶|逆转录酶]]而发挥抗病毒活性或抑制病毒特异性[[核糖核酸|RNA]]的合成，但却不影响病毒的吸附和穿入。金刚乙胺在[[肾|肾]]排泄前被[[代谢|代谢]]。

==相关药物==
*[[金刚烷胺|金刚烷胺]]

==外部連結==
* [http://www.fda.gov/bbs/topics/ANSWERS/ANS00530.html U.S. FDA press release announcing rimantadine's approval] {{Wayback|url=http://www.fda.gov/bbs/topics/ANSWERS/ANS00530.html |date=20050829181835 }}
* [https://web.archive.org/web/20050630080607/http://www.fda.gov/cder/drug/antivirals/influenza/flumadine.htm U.S. Center for Drug Evaluation and Research rimantadine description]
* [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a698029.html U.S. NIH rimantadine description]
* [http://www.cdc.gov/flu/professionals/treatment/index.htm U.S. CDC flu anti-viral treatment information]

{{抗病毒药物}}
{{RNA antivirals|state=autocollapse}}
{{抗帕金森病}}
{{Hallucinogens}}

[[category:抗病毒药物|category:抗病毒药物]]
[[Category:金刚烷基化合物|Category:金刚烷基化合物]]